Grifols stock steadies as the latest trial update stays in view
Published on 08/18/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols (ES0171996087) traded at $7.77 as of August 17, 2026, while its market capitalization was $5.29 billion and trading volume was 295,968 shares. The stock is also tied to a recent clinical update, with the company flagging completion of the SPARTA Phase 3 trial follow-up for Prolastin-C on August 10, 2026.
Trial data remains the key catalyst
MarketBeat listed Grifols at $7.77 at the August 17, 2026 close, and the same snapshot showed a 0.00% daily change. That keeps attention on whether the new SPARTA milestone can add a second leg to the half-year recovery story rather than just extend the recent headline flow.
For context, the quote page also showed a market cap of $5.29 billion, a price-to-earnings ratio of 40.89 and a beta of 0.67. The combination suggests a stock that still trades on event-driven sentiment even after the latest close.
Half-year numbers set the frame
Grifols' half-year 2026 results, carried in recent market coverage, showed revenue of $3.6 billion and adjusted EBITDA of $829 million, with leverage still a central investor focus. The same coverage said net profit improved sharply in the period, turning the company's balance-sheet rebuild into a major comparison point versus earlier years.
The half-year picture matters because it gives the stock a measurable base: revenue of $3.6 billion, adjusted EBITDA of $829 million and a market value of $5.29 billion. That is a concrete spread between operating scale and equity valuation, and it explains why every operational update now draws attention.
Balance sheet still matters
Recent financial-ratio data for Grifols showed EBITDA of 1,697.23 million in the latest annual series and total debt of 9,643 million in the same historical table. Historically, that debt load has been the number investors watch most closely when the shares react to trial news or profit updates.
Another recent market snapshot showed the shares at 6.690 EUR with a 5-day change of -0.30% and a year-to-date move of -2.89%. The broader message is simple: the stock still trades with a strong link to both execution and financing progress.
Prolastin-C stays central
Prolastin-C remains the product most closely associated with Grifols' alpha-1 antitrypsin franchise, and the SPARTA follow-up completion keeps that asset in the foreground. For investors, the question is whether that program supports a steadier earnings profile over time.
Grifols stock closed at $7.77 on August 17, 2026, and the quoted market cap stood at $5.29 billion. The latest move was flat, but the share price still sits inside a story shaped by clinical execution, debt and half-year operating results.
Investor relations
Company: Grifols, S.A.
ISIN: ES0171996087
Ticker: GRFS
Exchange: Nasdaq
Price (as of August 17, 2026, 4:00 p.m. ET): $7.77 USD
Market cap: $5.29 billion (as of August 17, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-listed healthcare stock
More on Grifols stock
The stock remains tied to Prolastin-C, the blood-plasma therapy used in alpha-1 antitrypsin deficiency. That franchise gives Grifols a visible product anchor while the market waits for the next earnings update.
